In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) closed at $9.98 in the last session, up 2.99% from day before closing price of $9.69. In other words, the price has increased by $2.99 from its previous closing price. On the day, 0.54 million shares were traded. BCYC stock price reached its highest trading level at $10.13 during the session, while it also had its lowest trading level at $9.0.
Ratios:
We take a closer look at BCYC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.81 and its Current Ratio is at 13.81. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $25.
On September 06, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $35.
B. Riley Securities Downgraded its Buy to Neutral on August 07, 2024, whereas the target price for the stock was revised from $33 to $28.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when Thompson Travis Alvin sold 2,686 shares for $15.00 per share. The transaction valued at 40,290 led to the insider holds 32,146 shares of the business.
Thompson Travis Alvin sold 1,750 shares of BCYC for $24,658 on Jan 02 ’25. The CHIEF ACCOUNTING OFFICER now owns 34,991 shares after completing the transaction at $14.09 per share. On Jan 03 ’25, another insider, Thompson Travis Alvin, who serves as the CHIEF ACCOUNTING OFFICER of the company, sold 159 shares for $14.75 each. As a result, the insider received 2,345 and left with 34,832 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCYC now has a Market Capitalization of 690639936 and an Enterprise Value of -179387504. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.54 while its Price-to-Book (P/B) ratio in mrq is 0.87. Its current Enterprise Value per Revenue stands at -5.085 whereas that against EBITDA is 0.885.
Stock Price History:
The Beta on a monthly basis for BCYC is 1.34, which has changed by -0.59348273 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, BCYC has reached a high of $28.67, while it has fallen to a 52-week low of $9.41. The 50-Day Moving Average of the stock is -18.98%, while the 200-Day Moving Average is calculated to be -49.45%.
Shares Statistics:
According to the various share statistics, BCYC traded on average about 396.19K shares per day over the past 3-months and 358170 shares per day over the past 10 days. A total of 69.06M shares are outstanding, with a floating share count of 61.30M. Insiders hold about 11.24% of the company’s shares, while institutions hold 53.64% stake in the company. Shares short for BCYC as of 1740700800 were 4218277 with a Short Ratio of 10.65, compared to 1738281600 on 4300447. Therefore, it implies a Short% of Shares Outstanding of 4218277 and a Short% of Float of 9.53.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
